Handbook of Therapeutic Antibodies

Stefan Dübel received his Ph.D. at the Center for Molecular Biology in Heidelberg, Germany, before moving on to the German Cancer Research Center in 1989 where he started research on the development of antibody libraries with naive or synthetic CDRs. In the following years, he substantially participated in the invention of antibody phage display, as well as other recombinant antibody technologies and the development of various antibody fusion proteins. In 1996, he moved to the University of Heidelberg to establish the antibody engineering group at the Institute of Molecular Genetics. He was appointed full professor at the Technische Universität Braunschweig in 2002, where he currently is head of the Department of Biotechnology and managing director of the Institute of Biochemistry, Biotechnology and Bioinformatics. He has co-authored more than 100 original papers, many patents, as well as several acknowledged textbooks in the field of recombinant antibodies. He is also on the editorial board of several scientific journals and cofounder of two antibody engineering companies.

Janice M. Reichert is an internationally recognized expert in the development of antibody therapeutics. She is Founder and Managing Director of Reichert Biotechnology Consulting LLC, a pharmaceutical business intelligence research firm, and the founding Editor-in-Chief of "mAbs", a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics and she has presented her research results as an invited speaker at conferences held worldwide. She is President of The Antibody Society and serves on the editorial boards of several biomedical journals. Dr. Reichert received her Ph.D. from the University of Pennsylvania and her post-doctoral training at Harvard Medical School.

Technologies

Foreword : Glassy

A Greeting from the Editor: Dübel

Introduction: Therapeutic Antibodies - From Past to Future Dübel


Part I: Selecting and Shaping the Antibody Molecule

Selection strategies I: Monoclonal Antibodies Moldenhauer

Selection strategies II: Phage Antibody Display Hust

Selection strategies III: Transgenic Mice Brüggemann

Bioinformatic Tools for Antibody Engineering Martin

Molecular Engineering I: Humanization Saldanha (X)

Molecular Engineering II: Affinity Maturation Roskos

Molecular Engineering III: Fc Engineering Valerius


Part II: Preparing The Way into the Clinic

Production and Downstream Processing Bergemann

Pharmaceutical Formulation and Clinical Application Reich

Immunogenicity of Antibody Therapeutics Schellekens

Glycoanalytics Beck (new)


Part III: Beyond IgG: Modified Antibodies

Immunoscintigraphy and Radioimmunotherapy Dearling

Bispecific Antibodies Kontermann

Immunotoxins /

Targeted RNases Rybak


Part IV: Emerging Concepts

Automation of Selection and Engineering Konthur

Emerging Technologies for Antibody Selection Taussig

Emerging Alternative Production Systems Jostock

Non-Antibody Scaffolds Skerra

Emerging Therapeutic Concepts I: ADEPT Sharma

Emerging Therapeutic Concepts II: Nanotechnology Dimitrov

Emerging Therapeutic Concepts III:Cell-bound antibodies Schirrmann

Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies Fischer

Recombinant Antibodies for target reserach Dübel (new)

Therapeutics


Part V: IP and regulatory issues

Antibody engineering Patents Braunagel

Quality standards of clinical studies Begent (new)

Regulatory issues of approving antibody therapeutics Shapiro (FDA)


Part VI: Ongoing Clinical Studies:

Antibodies in Phase I/II/III: Cancer Therapy Deckert

Antibodies in Phase I/II/III: Infectious Diseases N.N. (new)

Antibodies in Phase I/II/III: Targeting TNF Neurath


Part VII: Impact of Biosimilars of mAbs to innovative molecules N.N.

IP expiration landscape and Biosimilar pathways N.N.

High mAb Titer of Mammalian Cell Culture N.N.

Advanced DSP for mAb Production N.N.

Future mAb Manufacturing Facility: Flexibility and Feasible Sizes N.N.


Part VIII: Approved Antibodies

Serum Products Behrens (new)

Adalimumab (Humira) Kupper

Alemtuzumab (Mabcampath) Elter

Bevacizumab (Avastin) Díaz-Rubio

Cetuximab (Erbitux) Schleucher

Efalizumab (Raptiva) Jahn/Schmitt

Fanolesomab/Technetium99m (Neutrospec) Palestro

Gemtuzumab Ozogamicin (Mylotarg) Gramatzki/Peipp

Infliximab (Remicade) Antoni

Muromonab (Orthoclone) Becker

Natalizumab (Tysabri) Gold/Schimrigk

Omalizumab (Xolair) Kroegel

Palivizumab (Synagis) Schmidt AC

Rituximab (Rituxan) Wenger

Trastuzumab (Herceptin) Ellis

Plus 8-10 articles on new technologies and additional antibodies approved after print of first edition.

N.N. (new)

"...Das dreibändige Werk ist wirklich ausgesprochen gut gelungen...Jedem, der sich mit Antikörpern beschäftigt, ist dieses Buch wärmstens zu empfehlen."
Pharmazie in unserer Zeit, 09/2007